Dalbavancin as chronic antibiotic suppression therapy for left ventricular assist device driveline infection due to methicillin-resistant Staphylococcus aureus : a case report.

Autor:	Pallotto C; Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Department of Medicine and Surgery, University of Perugia, Perugia, Italy., Tordi S; Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Department of Medicine and Surgery, University of Perugia, Perugia, Italy., Pantanella R; Department of Cardiac Surgery, Santa Maria della Misericordia Hospital, Perugia, Italy., Rosignoli D; Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Department of Medicine and Surgery, University of Perugia, Perugia, Italy., Francisci D; Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Jazyk:	angličtina
Zdroj:	Journal of chemotherapy (Florence, Italy) [J Chemother] 2023 Sep; Vol. 35 (5), pp. 465-469. Date of Electronic Publication: 2022 Oct 25.
DOI:	10.1080/1120009X.2022.2136426
Abstrakt:	Left Ventricular Assist Devices (LVADs) represent an important therapeutic option in the management of advanced heart failure. We report a case of 74 years-old male with a Jarvik 2000® (Jarvik Heart, New York, USA) LVAD who presented with an infection of the LVAD driveline due to methicillin-resistant Staphylococcus aureus (MRSA) that was treated with dalbavancin as chronic antimicrobial suppression therapy without adverse events and maintaining a good quality of life for more than 37 weeks. Dalbavancin could represent a valid option for the treatment of LVAD infections because of its efficacy, pharmacokinetic/pharmacodynamic proprieties, safety and tolerability.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu